Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | IDO1 | P14902 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylhydrazine SCHEMBL28169534 | 1.00 | TDP1 (1.00) | TDP1IDO1CYP1A2CYP2C9CYP2C19 | |
| Phenylhydrazine SCHEMBL7099 | 1.00 | — | — | |
| Phenylhydrazine SCHEMBL1470567 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL8809529 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL304025 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL10885699 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL8861698 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL8809516 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL10936131 | 0.97 | — | — | |
| Phenylhydrazine SCHEMBL10317523 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202322-A1 | DRUG RELEASE COMPOSITIONS AND METHODS FOR DELIVERY | ABBOTT DIABETES CARE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10662155-B2 | Methods of preparing tecovirimat | SIGA TECHNOLOGIES INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190077753-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-10029985-B2 | Methods of preparing Tecovirimat | SIGA TECHNOLOGIES INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180086705-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662155-B2 | Methods of preparing tecovirimat | TYMP, NUDT1, HPRT1 | TDP1 157/4885IDO1 1748/4885CYP1A2 2677/4885 |
| US-20190077753-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | TDP1 157/4885IDO1 1748/4885CYP1A2 2677/4885 |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TDP1 2482/4885IDO1 2324/4885CYP1A2 2968/4885 |
| US-10029985-B2 | Methods of preparing Tecovirimat | TYMP, NUDT1, HPRT1 | TDP1 157/4885IDO1 1748/4885CYP1A2 2677/4885 |
| US-20220202322-A1 | DRUG RELEASE COMPOSITIONS AND METHODS FOR DELIVERY | EPHA2, CD47, ANXA6 | TDP1 787/4885IDO1 3518/4885CYP1A2 4125/4885 |
| US-20180086705-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | TDP1 157/4885IDO1 1748/4885CYP1A2 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.